Ordenar

Buscar

12/05/2026 Influence of Decreased Kidney Function on Plasma Biomarkers of Neurodegenerative Disorders in Routine Care: Confirmation of the Interest of Ratios
Mondésert, E, Cristol, JP, Bargnoux, AS, Duchiron, M, Busto, GU, Hirtz, C, Barnier-Figue, G, Perrein, F, Turpinat, C, Jurici, S, Gabelle, A, Bennys, K, Lehmann, S, Delaby, C. Influence of Decreased Kidney Function on Plasma Biomarkers of Neurodegenerative Disorders in Routine Care: Confirmation of the Interest of Ratios. NEUROLOGY. 2026; 106(9)DOI:10.1212/WNL.0000000000214931. PMID:41980230. IF:8.500(Q1/1D).
12/05/2026 Contribution of hospitals and clinical services to global warming: a scoping systematic review
Merino-Urrutia, W, Cárcamo-Fuentes, C, Peña, M, Zalej-Rakela, B, Rodríguez-García, J, Gottschalk-Cuevas, MD, Rubilar-Rocha, F, Martínez-Zapata, MJ. Contribution of hospitals and clinical services to global warming: a scoping systematic review. Frontiers in Public Health. 2026; 14DOI:10.3389/fpubh.2026.1778269. PMID:42205444. IF:3.400(Q1/2D).
07/05/2026 The role of Spanish clinical pharmacologists in economic evaluations of health technologies
Delgado-Espinoza, CE, Antonijoan, RM, Martínez-Zapata, MJ. The role of Spanish clinical pharmacologists in economic evaluations of health technologies. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2026; 82(6)DOI:10.1007/s00228-026-04070-2. PMID:42091708. IF:2.700(Q2/5D).
07/05/2026 Novel treatment strategies in cardiogenic shock: an update on ongoing clinical trials
Padilla-Lopez, M, Manicone, F, Holle, SLD, Wenzl, FA, Kimmoun, A, Mebazaa, A, Sionis, A. Novel treatment strategies in cardiogenic shock: an update on ongoing clinical trials. HEART FAILURE REVIEWS. 2026; 31(1)DOI:10.1007/s10741-026-10637-z. PMID:42095992. IF:4.200(Q1/3D).
04/05/2026 Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance
Barguilla, A, Riera, P, Ros-Castelló, V, Muino, E, Sierra-Marcos, A. Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance. Expert Review of Neurotherapeutics. 2026; 26(5)DOI:10.1080/14737175.2026.2647028. PMID:41875007. IF:3.400(Q2/3D).
04/05/2026 ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer
Provencio, M, Aguiar, D, Antoñanzas, M, Areses, MC, Azkárate, A, Barba, A, Bernabé, R, Blanco, R, Borregón, M, Campos, B, Coves, J, de Castro, J, Domènech, M, Dómine, M, Campelo, RG, Lucía-Gozálvez, C, Lázaro-Quintela, M, Insa, A, Juan-Vidal, O, Castro, RL, Martínez-Marti, A, Medina, S, Moreno, MA, Nadal, E, Olivares-Hernández, A, Reguart, N, Sala, MA, Medina, K, Vila, L, Massutí, B. ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY. 2026; 26(5)DOI:10.1080/14712598.2026.2677905. PMID:42159280. IF:4.000(Q2/3D).
04/05/2026 Phenotypic clustering of newly diagnosed type 2 diabetes in a Mediterranean cohort
Fernandez-Camins, B, Vlacho, B, Rojo-López, MI, Granado-Casas, M, Gratacòs, M, Ortega-Bravo, M, Cendros-Massioui, M, Palmieri, F, Perera-LLuna, A, Franch-Nadal, J, Mauricio, D. Phenotypic clustering of newly diagnosed type 2 diabetes in a Mediterranean cohort. Cardiovascular Diabetology. 2026; 25(1)DOI:10.1186/s12933-026-03198-w. PMID:42083025. IF:10.600(Q1/1D).
03/05/2026 Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer
Cella, L, Finocchiaro, A, Slusarczyk, A, Krajewski, W, Velasco, JC, Subiela, JD, Claps, F, Grobet-Jeandin, E, Del Giudice, F, Gallioli, A, Laukhtina, E, Marcq, G, Mari, A, Afferi, L, Albisinni, S, Soria, F, Hurle, R, Paciotti, M, Ferro, M, Perdonà, S, Mertens, LS, Moschini, M, Pradere, B, Contieri, R. Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. Future Oncology. 2026; 22(11)DOI:10.1080/14796694.2026.2661768. PMID:42041162. IF:2.600(Q3/6D).
02/05/2026 Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium
Baldi, GG, Giani, C, Ljevar, S, Denu, RA, Napolitano, A, Han, I, Brunello, A, Bhadri, V, Sebio, A, Andelkovic, V, Campos, F, Scanferla, R, Abreu, MH, Desar, IME, Ogura, K, Wong, DD, Bae, S, Bakhshi, S, Lefler, DS, Marquina, G, Mazzocca, A, Nakazawa, MS, Thway, K, Kim, HS, Chiusole, B, Connolly, EA, Terés, R, Antonescu, C, Bellan, E, Bovee, JVMG, Davis, JL, Tos, APD, Di Blasi, E, Lazar, AJ, Sbaraglia, M, Schaefer, IM, Taverna, S, Gronchi, A, Miceli, R, Chen, TW, Stacchiotti, S. Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium. EUROPEAN JOURNAL OF CANCER. 2026; 238DOI:10.1016/j.ejca.2026.116666. PMID:41819027. IF:7.100(Q1/2D).
01/05/2026 Biosynthetic Prosthesis Omniflow II in Chronic-Limb Threatening Ischemia: Results of the Multicenter National Registry Omni-Femoropopliteal
Baturone, A, Serrano, FJ, Camblor, LA, Alonso, M, García, F, Rodríguez, M, Marquina, R, Egaña, JM, Lozano, C, Landaluce, M, Garzón, N, Miralles, M, Fité, J, Escudero, JR, Olmos, D, Gomez-Palonés, F, Ligero, JM, Martín, A. Biosynthetic Prosthesis Omniflow II in Chronic-Limb Threatening Ischemia: Results of the Multicenter National Registry Omni-Femoropopliteal. ANNALS OF VASCULAR SURGERY. 2026; 126DOI:10.1016/j.avsg.2025.12.037. PMID:41544849. IF:1.600(Q2/5D).
01/05/2026 European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage
Vergouwen, MDI, Ramos-Pachon, A, Terecoasa, EO, Willett, N, Cuadrado-Godia, E, Gaberel, T, Gizewski, ER, Helbok, R, Ho, LA, Hugelshofer, M, Korja, M, Meling, TR, Psychogios, MN, Rinkel, GJE, Taschner, CA, Vajkoczy, P, Etminan, N. European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage. European Stroke Journal. 2026; 11(5)DOI:10.1093/esj/aakag043. PMID:42095754. IF:4.500(Q1/2D).
01/05/2026 KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs
Volta-Durán, E, Alba-Castellon, L, Arena, LA, Sánchez, JM, Casanova, I, Mangues, R, Villaverde, A, Vázquez, E, Unzueta, U. KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2026; 222DOI:10.1016/j.ejpb.2026.115020. PMID:41690333. IF:4.300(Q1/2D).
01/05/2026 Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis (Jan, 10.1007/s12325-026-03490-x, 2026)
Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis (Jan, 10.1007/s12325-026-03490-x, 2026). ADVANCES IN THERAPY. 2026; 43(5)DOI:10.1007/s12325-026-03532-4. PMID:41817916. IF:4.000(Q1/3D).
01/05/2026 Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial
Behrens, GMN, Assoumou, L, Liegeon, G, Antinori, A, Micán, R, Genderini, FG, Post, FA, Rockstroh, JK, Hamzah, L, Domingo, P, Curran, A, Laguno, M, Fletcher, C, Moody, J, Pozniak, A. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial. LANCET INFECTIOUS DISEASES. 2026; 26(5)DOI:10.1016/S1473-3099(25)00681-4. PMID:41344354. IF:31.000(Q1/1D).
01/05/2026 Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases
Novello, S, Rabinovich, NM, Shih, JY, Pelizzari, G, Stevenson, J, Majem, M, Ferreira, CG, Petty, WJ, Arriola, E, Castagneris, N, De Castro, J, Morbeck, I, Bauman, J, Toschi, L, Zer, A, Metro, G, Kalmadi, S, Martinez, AA, Al Husaini, H, Meloni, AR, Nduka, C, Ardito-Abraham, C, Xia, CH, Awad, MM. Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases. Jto Clinical And Research Reports. 2026; 7(5)DOI:10.1016/j.jtocrr.2026.100974. PMID:42006282. IF:(Q/D).
01/05/2026 Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
Espinosa, E, Berciano-Guerrero, MA, Muñoz-Couselo, E, Puértolas, T, Manzano, JL, Soria, A, De Miguel, PA, Crespo, G, Sanz, LG, Cerezuela-Fuentes, P, de la Rosa, CA, Majem, M, Castaño, AG, Berrocal, A, Arroyo, FRG, de la Borbolla, MR, Bellido, L, Martínez, JM, Fernández, LA, Carnicero, AM, Castro, RL, Rodríguez, AB, Lecumberri, MJ, Guzmán, JCV, Balea, BC, Rodríguez, JF, Bautista, JV, Pérez, VN, Mujika, K, Subias, MC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clinical & Translational Oncology. 2026; 28(5)DOI:10.1007/s12094-025-04098-3. PMID:41313559. IF:2.500(Q3/6D).
01/05/2026 Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
Gillessen, S, Gallardo, E, Choudhury, A, Saad, F, Soares, A, Loriot, Y, McDermott, R, Rodriguez-Vida, A, Velho, PI, Nolè, F, Cruz, F, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Veiga, FG, Skoneczna, I, da Trindade, KM, Carcano, FM, Lecouvet, F, Coens, C, Poncet, C, Fournier, B, Tombal, B. Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer. ANNALS OF ONCOLOGY. 2026; 37(5)DOI:10.1016/j.annonc.2026.02.009. PMID:41763609. IF:65.400(Q1/1D).
01/05/2026 Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT
Cesaro, S, Garonzi, C, Tridello, G, Verheggen, I, Liu, DH, Flynn, C, Alahmari, A, Kaynar, L, Rabitsch, W, Uygun, V, Chorao, P, Hu, J, Esquirol, A, Piñana, JL, Aljurf, M, Wagner-Drouet, E, Lang, PT, Martin-Sanchez, G, Ratip, S, Facchini, L, Nasilowska-Adamska, B, Styczynski, J, Ram, R, Metafuni, E, Tanase, A, Kalwak, K, Serio, B, Hashem, H, Castagna, L, Vicent, MG, Karakukcu, M, Halahleh, K, Baltadakis, I, Benedetti, E, Mikulska, M, de la Camara, R, Averbuch, D. Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT. BONE MARROW TRANSPLANTATION. 2026; 61(5)DOI:10.1038/s41409-026-02832-1. PMID:41888297. IF:5.200(Q1/1D).
01/05/2026 Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases
Domínguez, JMG, Villar, LM, Arrambide, G, Blanco, Y, Calles, MC, Casanova, B, Castillo-Triviño, T, França, LCF, Eichau, S, Pérez, MAH, Landete, L, Lallana, JM, Oreja-Guevara, C, Prieto, JM, Querol, L, Caminero, AB. Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases. NEUROLOGIA. 2026; 41(4)DOI:10.1016/j.nrl.2025.501928. PMID:. IF:3.100(Q2/4D).
01/05/2026 Low-intervention clinical trials in Spain: Do they progress?
Delgado-Espinoza, CE, Pestana, MJC, Amaro, K, Antonijoan, RM, Pontes, C. Low-intervention clinical trials in Spain: Do they progress?. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2026; 92(5)DOI:10.1002/bcp.70409. PMID:41406957. IF:3.000(Q2/4D).